about
Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061Prevention of HIV-1 infection with early antiretroviral therapyA universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human bloodHIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043).Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trialEffects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialFailure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screeningEmergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043).Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenHIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study.Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trialPerformance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern AfricaAnalysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trialDetermination of HIV Status in African Adults With Discordant HIV Rapid Tests.Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessmentHPTN 068: A Randomized Control Trial of a Conditional Cash Transfer to Reduce HIV Infection in Young Women in South Africa-Study Design and Baseline Results.Sexual Partnership Patterns Among South African Adolescent Girls Enrolled in HPTN [corrected] 068: Measurement Challenges and Implications for HIV/STI Transmission.Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial.Transactional sex among young women in rural South Africa: prevalence, mediators and association with HIV infection.Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).Antiretroviral Therapy for the Prevention of HIV-1 TransmissionDetection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay.Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection.Concomitant socioeconomic, behavioral, and biological factors associated with the disproportionate HIV infection burden among Black men who have sex with men in 6 U.S. cities.A Comparison of Hepatitis B Virus Infection in HIV-infected and HIV-uninfected Participants Enrolled in a Multi-National Clinical Trial: HPTN 052.Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South AfricaHIV-1 plasma RNA level and CD4 cell count in a large urban HIV-1-infected patient population from 1997 to 2000.Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays.Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043).Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load.Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.Erratum to: Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessmentComparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole blood.A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
P50
Q21132664-E6739967-BC20-4897-A860-5EEA28899010Q24634688-844D9421-A9EC-4437-9891-2EC1DE827604Q33626374-EA6C35B5-FF06-4D38-8A31-15C60C820BCDQ33648264-A69FE48E-3776-4BC0-BEE5-985E6828ED68Q33690506-0A3A01FB-0751-4818-BD9E-F51542BFFFE3Q34028918-5E7831EC-BD5F-40BE-B996-3410EA38A398Q34038548-572E6E41-95D9-46F8-A2F2-0F416186E0BDQ34086963-E76217A9-2C91-40BC-A8A9-EEECE0F171C7Q34205686-C9BE7BBE-3970-4D3C-80BB-81CA2B0F03C8Q34726928-B2474965-A8EF-4670-BC90-7A2D46F8EB0FQ34848161-68040A7F-561A-461A-AFA9-544938418683Q34874237-1415780C-4B0F-4273-9398-1ED8634C57B8Q35004616-A681D7B4-DCA0-4325-88F5-7D7BBD118DC5Q35043592-15D2BB15-EB2C-4F06-AB9A-0AA169A045B2Q35056570-3760CEBA-7B4E-408D-99BA-052E123B7573Q35532840-B341CF0C-CE32-4F1E-A6BB-2489058AE311Q35789047-F9B06B0B-6D60-40AF-8439-241D363AB5D7Q35794339-63A0A9CC-8F42-4ABA-84DB-1D0BF568FE69Q35927705-4218494A-8AE7-41FE-B970-0A6732F0B392Q36169338-AD0B9BAE-A7F6-4506-AFE2-2BECA20E2F8CQ37014155-72410D63-B575-448C-9D78-ECE494E42379Q37136842-7ECD957A-E396-4AB5-B773-D50AED0E6278Q37247477-EFEA2D01-995D-47A2-A64F-C51840824B54Q37308674-A38DFB66-D859-488C-A27C-A618147AD981Q37347026-AA902971-E0F0-48C7-BD54-9094DAC8BCAFQ37395586-262C2BC7-D609-4B31-852A-3ADFDD789176Q37538662-9B59ADF3-464F-4259-9E72-90205086C244Q38657651-59F44751-FE72-4669-B65B-74A5216DC876Q38912662-934C21EA-2EF3-4959-B7C9-709F5E521D70Q39669495-E26FD50B-A0EA-4AEE-AE75-9681E6DF5E53Q40226580-4BF2F902-67A1-420F-BCE3-BC1F5D6C00DDQ40239354-3DB62026-D536-48A7-B990-C3327EB8166DQ40281007-F3CF58C9-1EE8-4493-A12D-AC5B04B15D1FQ40458433-D9420C31-EBD6-4455-BB6E-765CFB9669E6Q40572857-B7D82DAC-3E42-4DE7-9723-A2DEF1154A58Q40938175-3E626CF2-1387-41BF-8A1F-2FFD4548447DQ41990298-537FB3B5-7342-45AC-9CEF-39393639AFC0Q42348733-813A99C1-EA54-419D-A63D-12FCFE79A786Q43077364-40E59B4A-0443-45BD-8CC7-F360F0DBD426Q43817018-953F9BBC-0390-4CDA-AD65-5A50D8B4B449
P50
description
researcher ORCID ID = 0000-0002-6501-0440
@en
wetenschapper
@nl
name
Estelle Piwowar-Manning
@ast
Estelle Piwowar-Manning
@en
Estelle Piwowar-Manning
@es
Estelle Piwowar-Manning
@nl
type
label
Estelle Piwowar-Manning
@ast
Estelle Piwowar-Manning
@en
Estelle Piwowar-Manning
@es
Estelle Piwowar-Manning
@nl
prefLabel
Estelle Piwowar-Manning
@ast
Estelle Piwowar-Manning
@en
Estelle Piwowar-Manning
@es
Estelle Piwowar-Manning
@nl
P21
P31
P496
0000-0002-6501-0440